Despite the significant improvement in the survival of HER2-positive breast cancer patients following the introduction of anti-HER2-targeted therapies, long-term follow-up data indicate that approximately a quarter of patients will relapse [4]. This evidence concerns the gene ERBB2 and breast cancer.